Allogene Therapeutics, Inc. (ALLO) shareholders
ALLONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.84+0.01 (+1.41%)
Close on Nov 13, 2026Market cap $289.76MP/E –Yield 0.00%
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
90.5%
313M of 345M shares
Institutional holders
209
32 new, 28 sold out
Net institutional buying
129M
In Q2 2026
Insider trades, 12 months
0 buys · 15 sales
Net sold $668.81K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Abigail P. Johnson Joint filing with FMR LLC (11.30%) | 23,771,995 | 11.30% | 13G (passive) amendment | Dec 31, 2024 |
| BlackRock, Inc. | 23,211,736 | 6.70% | 13G (passive) amendment | Sep 30, 2026 |
| Pfizer Inc. | 22,032,040 | 9.00% | 13D (active) amendment | Nov 6, 2025 |
| Frazier Life Sciences Public Fund, L.P. Joint filing with Fhmlsp, L.P. (5.60%), Fhmlsp, L.L.C. (5.60%) | 19,445,046 | 5.60% | 13G (passive) amendment | Jun 30, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of ALLO | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 30,146,963 | 8.73% | $62.71M | +11,055,868 | 0.00% |
| Frazier Life Sciences Management, L.P. | 22,446,668 | 6.50% | $46.69M | +18,650,000 | 1.02% |
| Pfizer Inc | 22,032,040 | 6.38% | $46.93M | – | 27.55% |
| State Street Corp | 19,025,826 | 5.51% | $39.57M | +10,365,520 | 0.00% |
| Tpg Gp A, LLC | 18,716,306 | 5.42% | $38.93M | – | 0.78% |
| Sio Capital Management, LLC | 13,323,431 | 3.86% | $27.71M | New | 4.59% |
| Primecap Management Co/Ca/ | 13,123,440 | 3.80% | $27.30M | +4,743,600 | 0.02% |
| Vanguard Capital Management LLC | 12,166,636 | 3.52% | $25.31M | +5,245,286 | 0.00% |
| FMR LLC | 12,009,043 | 3.48% | $24.98M | +10,419,213 | 0.00% |
| Citadel Advisors LLC | 10,087,770 | 2.92% | $20.98M | +3,294,150 | 0.00% |
| Two Sigma Investments, LP | 7,784,348 | 2.25% | $16.19M | +2,408,892 | 0.01% |
| Geode Capital Management, LLC | 7,049,328 | 2.04% | $14.67M | +2,925,150 | 0.00% |
| Goldman Sachs Group Inc | 6,148,959 | 1.78% | $12.79M | +3,382,715 | 0.00% |
| GordonMD Global Investments LP | 5,298,000 | 1.53% | $11.02M | +3,868,000 | 5.33% |
| Marshall Wace, Llp | 5,095,408 | 1.47% | $10.60M | +1,647,424 | 0.01% |
| Patient Square Capital LP | 5,050,000 | 1.46% | $10.50M | +1,600,000 | 1.63% |
| abrdn plc | 5,001,752 | 1.45% | $10.40M | +3,539,533 | 0.01% |
| Millennium Management LLC | 4,843,889 | 1.40% | $10.08M | +1,521,836 | 0.00% |
| D. E. Shaw & Co., Inc. | 4,710,735 | 1.36% | $9.80M | +1,946,959 | 0.00% |
| Price T Rowe Associates Inc /Md/ | 4,639,283 | 1.34% | $9.65M | −741,619 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 209 | 313M | 90.5% | 32 / 99 | 51 / 28 | 140M | 12M |
| Q1 2026 | 209 | 184M | 53.3% | 51 / 79 | 41 / 12 | 50M | 19M |
| Q4 2025 | 172 | 163M | 47.2% | 29 / 52 | 47 / 20 | 17M | 15M |
| Q3 2025 | 170 | 163M | 47.2% | 30 / 61 | 37 / 16 | 23M | 45M |
| Q2 2025 | 158 | 185M | 53.5% | 16 / 52 | 46 / 27 | 7M | 20M |
| Q1 2025 | 171 | 197M | 57.1% | 28 / 65 | 40 / 29 | 37M | 28M |
| Q4 2024 | 174 | 189M | 54.6% | 32 / 62 | 42 / 14 | 40M | 20M |
| Q3 2024 | 156 | 168M | 48.8% | 11 / 59 | 48 / 28 | 30M | 14M |
| Q2 2024 | 175 | 169M | 49.0% | 30 / 65 | 43 / 15 | 41M | 13M |
| Q1 2024 | 161 | 141M | 40.8% | 23 / 56 | 45 / 32 | 26M | 16M |
| Q4 2023 | 170 | 131M | 37.9% | 40 / 51 | 51 / 22 | 22M | 21M |
| Q3 2023 | 154 | 130M | 37.7% | 13 / 67 | 37 / 29 | 8M | 11M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
155 funds held ALLO in Q2 2026, 50% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of ALLO | Value | % of fund | As of |
|---|---|---|---|---|---|
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 12,142,998 | 3.51% | $25.26M | 0.24% | Jun 30, 2026 |
| Select Biotechnology Portfolio | 9,546,893 | 2.76% | $20.72M | 0.39% | May 31, 2026 |
| Vanguard Capital Opportunity Fund | 9,388,170 | 2.72% | $19.53M | 0.06% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 8,666,591 | 2.51% | $18.03M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 6,916,407 | 2.00% | $14.39M | 0.02% | Jun 30, 2026 |
| PRIMECAP Odyssey Aggressive Growth Fund | 3,475,270 | 1.01% | $6.53M | 0.09% | Jul 31, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 3,444,101 | 1.00% | $7.16M | 0.06% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 3,223,886 | 0.93% | $6.71M | 0.01% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 2,909,372 | 0.84% | $5.47M | 0.02% | Jul 31, 2026 |
| iShares Russell 2000 Value ETF | 2,479,776 | 0.72% | $5.16M | 0.04% | Jun 30, 2026 |
| iShares Biotechnology ETF | 1,803,716 | 0.52% | $3.75M | 0.04% | Jun 30, 2026 |
| Columbia Small Cap Value Discovery Fund | 1,798,280 | 0.52% | $3.38M | 0.14% | Jul 31, 2026 |
| BlackRock Advantage Small Cap Core Fund | 1,442,118 | 0.42% | $3.13M | 0.06% | May 29, 2026 |
| Fidelity Enhanced Small Cap Core ETF | 1,438,234 | 0.42% | $2.99M | 0.05% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 1,317,691 | 0.38% | $2.86M | 0.01% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| David D. Chang | President and CEO, Director | 6,351,707 | 1.84% | Mar 18, 2026 |
| Geoffrey M. Parker | CHIEF FINANCIAL OFFICER | 1,045,877 | 0.30% | Oct 23, 2026 |
| Earl Martin Douglas | SVP, General Counsel | 488,267 | 0.14% | Aug 25, 2026 |
| Zachary Roberts | President and CEO | 581,166 | 0.17% | Jul 6, 2026 |
| Annie Yoshiyama | SVP, Finance | 124,517 | 0.04% | Apr 23, 2026 |
| Benjamin Machinas Beneski | SVP, Chief Technical Officer | 195,338 | 0.06% | Apr 2, 2026 |
| Timothy L. Moore | Chief Technical Officer | 250,713 | 0.07% | Feb 5, 2025 |
| Franz B. Humer | Director | 307,507 | 0.09% | Jun 23, 2026 |
| Owen N. Witte | Director | 292,832 | 0.08% | Jun 23, 2026 |
| Joshua A. Kazam | Director | 398,463 | 0.12% | Jun 23, 2026 |
| Elizabeth A. Barrett | Director | – | – | Jun 23, 2026 |
| Stephen Mayo | Director | 25,328 | 0.01% | Jun 23, 2026 |
| Vicki L. Sato | Director | 162,575 | 0.05% | Jun 23, 2026 |
| Deborah M. Messemer | Director | 113,966 | 0.03% | Jun 23, 2026 |
| Arie Belldegrun | Director | 6,946,936 | 2.01% | Feb 4, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Geoffrey M. Parker CHIEF FINANCIAL OFFICER | Oct 21, 2026 | Sale | −36,342 | $1.34 | $48.70K | 1,045,877 |
| Earl Martin Douglas SVP, General Counsel | Aug 21, 2026 | Sale | −29,697 | $2.12 | $62.96K | 488,267 |
| Joshua A. Kazam Director | Jun 18, 2026 | Option exercise | +47,700 | – | – | 398,463 |
| Annie Yoshiyama SVP, Finance | Apr 21, 2026 | Sale | −9,586 | $2.31 | $22.14K | 124,517 |
| Benjamin Machinas Beneski SVP, Chief Technical Officer | Mar 31, 2026 | Sale | −2,867 | $2.50 | $7.17K | 195,338 |
| David D. Chang President and CEO, Director | Mar 16, 2026 | Sale | −47,763 | $2.47 | $117.97K | 5,150,599 |
| Benjamin Machinas Beneski SVP, Chief Technical Officer | Mar 16, 2026 | Sale | −4,835 | $2.47 | $11.94K | 198,205 |
| Benjamin Machinas Beneski SVP, Chief Technical Officer | Mar 2, 2026 | Sale | −7,132 | $2.60 | $18.54K | 203,040 |
| Annie Yoshiyama SVP, Finance | Feb 2, 2026 | Sale | −4,167 | $1.72 | $7.17K | 130,322 |
| David D. Chang President and CEO, Director | Feb 2, 2026 | Sale | −95,269 | $1.80 | $171.48K | 5,185,862 |
| Zachary Roberts EVP of R&D | Feb 2, 2026 | Sale | −35,700 | $1.77 | $63.19K | 581,166 |
| Geoffrey M. Parker CHIEF FINANCIAL OFFICER | Feb 2, 2026 | Sale | −24,001 | $1.76 | $42.24K | 1,252,795 |
| Benjamin Machinas Beneski SVP, Chief Technical Officer | Feb 2, 2026 | Sale | −7,549 | $1.73 | $13.06K | 210,172 |
| Earl Martin Douglas SVP, General Counsel | Feb 2, 2026 | Sale | −22,900 | $1.76 | $40.30K | 564,948 |
| Zachary Roberts EVP of R&D | Jan 21, 2026 | Sale | −26,269 | $1.56 | $40.98K | 616,866 |
| Joshua A. Kazam Director | Dec 18, 2025 | Option exercise | +47,700 | – | – | 350,763 |
| Benjamin Machinas Beneski SVP, Chief Technical Officer | Nov 17, 2025 | Sale | −786 | $1.22 | $959 | 217,721 |
| Geoffrey M. Parker CHIEF FINANCIAL OFFICER | Oct 21, 2025 | Sale | −36,744 | $1.26 | $46.30K | 1,276,796 |
| Deborah M. Messemer Director | Jun 10, 2025 | Sale(10b5-1 plan) | −36,885 | $1.42 | $52.38K | 107,431 |
| Annie Yoshiyama SVP, Finance | Apr 21, 2025 | Sale | −9,601 | $1.41 | $13.54K | 130,663 |
| David D. Chang President and CEO, Director | Mar 14, 2025 | Sale | −46,668 | $1.96 | $91.47K | 5,276,569 |
| Benjamin Machinas Beneski SVP, Chief Technical Officer | Mar 14, 2025 | Sale | −5,488 | $1.98 | $10.87K | 218,507 |
| Benjamin Machinas Beneski SVP, Chief Technical Officer | Mar 1, 2025 | Award | +31,755 | – | – | 223,995 |
| Deborah M. Messemer Director | Feb 18, 2025 | Sale(10b5-1 plan) | −13,313 | $2.43 | $32.35K | 144,316 |
| Zachary Roberts EVP of R&D | Feb 3, 2025 | Sale | −18,832 | $1.70 | $32.01K | 643,135 |
| Timothy L. Moore Chief Technical Officer | Feb 3, 2025 | Sale | −14,746 | $1.71 | $25.22K | 250,713 |
| Geoffrey M. Parker CHIEF FINANCIAL OFFICER | Feb 3, 2025 | Sale | −4,361 | $1.73 | $7.54K | 1,301,540 |
| Earl Martin Douglas SVP, General Counsel | Feb 3, 2025 | Sale | −6,404 | $1.71 | $10.95K | 587,848 |
| David D. Chang President and CEO, Director | Feb 3, 2025 | Sale | −46,003 | $1.68 | $77.29K | 5,317,237 |
| Geoffrey M. Parker CHIEF FINANCIAL OFFICER | Jan 24, 2025 | Award | +173,913 | – | – | 1,305,901 |
| David D. Chang President and CEO, Director | Jan 24, 2025 | Award | +552,174 | – | – | 5,363,240 |
| Zachary Roberts EVP of R&D | Jan 24, 2025 | Award | +173,913 | – | – | 661,967 |
| Earl Martin Douglas SVP, General Counsel | Jan 24, 2025 | Award | +144,928 | – | – | 594,252 |
| Arie Belldegrun Director | Jan 24, 2025 | Award | +369,957 | – | – | 2,236,816 |
| Annie Yoshiyama SVP, Finance | Jan 24, 2025 | Award | +36,232 | – | – | 137,990 |
| Zachary Roberts EVP of R&D | Jan 21, 2025 | Sale | −27,199 | $1.78 | $48.41K | 488,054 |
| Deborah M. Messemer Director | Dec 9, 2024 | Sale(10b5-1 plan) | −9,136 | $2.18 | $19.92K | 157,629 |
| Franz B. Humer Director | Dec 5, 2024 | Sale | −9,221 | $2.16 | $19.92K | 307,507 |
| Geoffrey M. Parker CHIEF FINANCIAL OFFICER | Oct 21, 2024 | Tax withholding | −36,404 | $2.84 | $103.39K | 1,131,988 |
| Earl Martin Douglas SVP, General Counsel | Aug 21, 2024 | Tax withholding | −28,310 | $2.79 | $78.98K | 449,324 |
| Deborah M. Messemer Director | Jun 18, 2024 | Sale(10b5-1 plan) | −18,641 | $2.28 | $42.50K | 166,765 |
| Deborah M. Messemer Director | Jun 5, 2024 | Award | +122,950 | – | – | 185,406 |
| Franz B. Humer Director | Jun 5, 2024 | Award | +61,475 | – | – | 316,728 |
| Vicki L. Sato Director | Jun 5, 2024 | Award | +61,475 | – | – | 162,575 |
| Franz B. Humer Director | May 30, 2024 | Sale | −11,200 | $2.34 | $26.21K | 255,253 |
| David D. Chang President and CEO, Director | May 16, 2024 | Award | +344,828 | $2.90 | $1.00M | 4,810,106 |
| Arie Belldegrun Director | May 16, 2024 | Award | +344,828 | $2.90 | $1.00M | 539,867 |
| Arie Belldegrun Director | May 16, 2024 | Buy | +1,724,137 | $2.90 | $5.00M | 1,724,137 |
| Geoffrey M. Parker CHIEF FINANCIAL OFFICER | May 16, 2024 | Award | +344,828 | $2.90 | $1.00M | 1,164,418 |
| Timothy L. Moore Chief Technical Officer | Apr 22, 2024 | Tax withholding | −17,360 | $3.47 | $60.24K | 265,459 |
| David D. Chang President and CEO, Director | Mar 14, 2024 | Tax withholding | −53,393 | $4.33 | $231.19K | 4,465,278 |
| Geoffrey M. Parker CHIEF FINANCIAL OFFICER | Jan 30, 2024 | Buy | +190 | $3.60 | $684 | 819,590 |
| Earl Martin Douglas SVP, General Counsel | Jan 25, 2024 | Award | +41,800 | – | – | 477,634 |
| Timothy L. Moore Chief Technical Officer | Jan 25, 2024 | Award | +96,600 | – | – | 282,819 |
| David D. Chang President and CEO, Director | Jan 25, 2024 | Award | +317,800 | – | – | 4,513,203 |
| Arie Belldegrun Director | Jan 25, 2024 | Award | +211,973 | – | – | 1,866,859 |
| Geoffrey M. Parker CHIEF FINANCIAL OFFICER | Jan 25, 2024 | Award | +29,400 | – | – | 819,400 |
| Zachary Roberts EVP of R&D | Jan 25, 2024 | Award | +140,000 | – | – | 515,253 |
| Zachary Roberts EVP of R&D | Jan 22, 2024 | Tax withholding | −24,690 | $3.17 | $78.27K | 375,253 |
| Deborah M. Messemer Director | Dec 18, 2023 | Sale(10b5-1 plan) | −18,640 | $2.70 | $50.33K | 62,456 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Short % of float
17.47%
51M shares short
Days to cover
6.2
At 8M shares a day
Change since last report
-4.0%
From 53M shares
Short volume, 20 days
31.5%
Of volume reported to FINRA
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Allogene Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 6,505,279 shares on Sep 29, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Geoffrey M. Parker Officer | Oct 21, 2026 | 36,342 | $48.70K | Oct 21, 2026 | Vesting of restricted stock unit award |
| Earl Martin Douglas Officer | Aug 21, 2026 | 29,697 | $62.96K | Aug 21, 2026 | Vesting of restricted stock unit award |
| Annie Yoshiyama Officer | Apr 21, 2026 | 9,586 | $22.10K | Apr 21, 2026 | Vesting of restricted stock unit award |
| Benjamin Machinas Beneski Officer | Apr 1, 2026 | 2,867 | $7.17K | Apr 1, 2026 | Vesting of restricted stock unit award |
| David D. Chang Officer | Mar 16, 2026 | 47,763 | $117.83K | Mar 16, 2026 | Vesting of restricted stock unit award |
| Benjamin Machinas Beneski Officer | Mar 16, 2026 | 4,835 | $11.93K | Mar 16, 2026 | Vesting of restricted stock unit award |
| Benjamin Machinas Beneski Officer | Mar 2, 2026 | 7,132 | $18.54K | Mar 2, 2026 | Vesting of restricted stock unit award |
| Benjamin Machinas Beneski Officer | Feb 2, 2026 | 16,823 | $29.05K | Feb 2, 2026 | Restricted stock vesting under a registered plan |
| David D. Chang Officer | Feb 2, 2026 | 243,976 | $438.52K | Feb 2, 2026 | Restricted stock vesting under a registered plan |
| Zachary Roberts Officer | Feb 2, 2026 | 35,700 | $63.35K | Feb 2, 2026 | Restricted stock vesting under a registered plan |
| Annie Yoshiyama Officer | Feb 2, 2026 | 4,167 | $7.18K | Feb 2, 2026 | Restricted stock vesting under a registered plan |
| Geoffrey M. Parker Officer | Feb 2, 2026 | 24,001 | $42.19K | Feb 2, 2026 | Restricted stock vesting under a registered plan |
| Earl Martin Douglas Officer | Feb 2, 2026 | 22,900 | $40.21K | Feb 2, 2026 | Restricted stock vesting under a registered plan |
| Zachary Roberts Officer | Jan 21, 2026 | 26,269 | $40.93K | Jan 21, 2026 | Vesting of restricted stock unit award |
| Benjamin Machinas Beneski Officer | Nov 17, 2025 | 786 | $959 | Nov 17, 2025 | Vesting of restricted stock unit award |
See a number that looks wrong?